Cristina Gasparetto, MD

Articles by Cristina Gasparetto, MD

Proteasome Inhibition in MM: In-Class Transition From Bortezomib to Ixazomib

ByPaul G. Richardson, MD,Cristina Gasparetto, MD

March 28th 2022

Experts Paul Richardson, MD, and Cristina Gasparetto, MD, discuss trial data analyzing the in-class transition from bortezomib to ixazomib for patients with multiple myeloma.

TOURMALINE-MM1: Ixazomib Therapy in Relapsed/Refractory MM

ByPaul G. Richardson, MD,Cristina Gasparetto, MD

March 28th 2022

Expert perspectives on data from the TOURMALINE-MM1 trial, which tested ixazomib therapy in patients with relapsed/refractory multiple myeloma.

Multiple Myeloma: Real-World Data With Proteasome Inhibitors

ByCristina Gasparetto, MD,Paul G. Richardson, MD

March 21st 2022

Shared insight on how real-world experience and data with proteasome inhibitors in multiple myeloma compare to what was seen in clinical trials.

An Overview of Proteasome Inhibitor Therapy in Multiple Myeloma

ByPaul G. Richardson, MD,Cristina Gasparetto, MD

March 21st 2022

A broad look at the historical use of proteasome inhibitor therapy in patients with multiple myeloma centered on 3 agents: bortezomib, carfilzomib, and ixazomib.

Optimizing Therapy in Frontline Multiple Myeloma Not Eligible for Transplant

ByC. Ola Landgren, MD, PhD,Craig Hofmeister, MD, MPH,Cristina Gasparetto, MD,Peter Voorhees, MD

December 24th 2021

Experts in the multiple myeloma field discuss which front-line therapy is best for patients who are treatment ineligible.

Future Directions in Multiple Myeloma Care: Improvements and Unmet Needs

ByC. Ola Landgren, MD, PhD,Cristina Gasparetto, MD,Craig Hofmeister, MD, MPH,Peter Voorhees, MD

October 21st 2021

After reviewing implications of the MAIA study in multiple myeloma, experts consider unmet needs and future directions in care.

Patient Case #2: A 77-Year-Old Man With Newly Diagnosed MM

ByC. Ola Landgren, MD, PhD,Cristina Gasparetto, MD,Craig Hofmeister, MD, MPH,Peter Voorhees, MD

October 21st 2021

Panelists discuss the case of a 77-year-old man with newly diagnosed multiple myeloma who wishes to discontinue therapy after achieving a very good partial response.

Patient Case #1: A 75-Year-Old Woman With Newly Diagnosed MM

ByC. Ola Landgren, MD, PhD,Cristina Gasparetto, MD,Craig Hofmeister, MD, MPH,Peter Voorhees, MD

October 14th 2021

Experts review the case of a 75-year-old woman with newly diagnosed multiple myeloma and discuss treatment selection, continuation, reduction, and duration.

Treatment Options for First-Line Therapy in Transplant-Ineligible MM

ByC. Ola Landgren, MD, PhD,Cristina Gasparetto, MD,Craig Hofmeister, MD, MPH,Peter Voorhees, MD

October 14th 2021

In-depth considerations for available frontline therapy regimens for patients with transplant-ineligible multiple myeloma.

Transplant-Ineligible MM: Treatment After Adequate Response to Therapy

ByC. Ola Landgren, MD, PhD,Cristina Gasparetto, MD,Craig Hofmeister, MD, MPH,Peter Voorhees, MD

October 7th 2021

A panel of experts reflects on appropriate actions to take after a patient achieves adequate response to therapy for transplant-ineligible multiple myeloma.